Home  »  Finance   »  What You Didn’t Know About Citius Pharmaceut...

What You Didn’t Know About Citius Pharmaceuticals Inc. (NASDAQ: CTXR) This Week

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) traded at $1.40 at close of the session on Monday, 01/23/23, made an upward move of 1.45% on its previous day’s price.

Looking at the stock we see that its previous close was $1.38 and the beta (5Y monthly) reads 1.26 with the day’s price range being $1.30 – $1.40. In terms of its 52-week price range, CTXR has a high of $2.01 and a low of $0.77. The company’s stock has gained about 34.62% over that past 30 days.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Citius Pharmaceuticals Inc. has a market cap of $207.66 million and is expected to release its quarterly earnings report on Feb 08, 2023 – Feb 13, 2023. Estimates by analysts give the company expected earnings per share (EPS) of -$0.04, with the EPS growth for the year raised at -$0.2 for 2022 and $0.41 for next year. These figures represent 4.80% and 305.00% growth in EPS for the two years respectively.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the CTXR stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Buy.

Based on estimates by 2 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Citius Pharmaceuticals Inc. (CTXR) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is 42.64% off its SMA20 and 30.99% from its 50-day simple moving average. The RSI (14) is pointing at 76.03 while the volatility over the past week is 12.99% and jumps to 10.04% over the past one month. The beta value is 1.27, while the average true range (ATR) is currently pointing at 0.10. The average price target for the stock over the next 12 months is $7.00, with the estimates having a low of $4.00 and a high of $10.00. These price ends are -185.71% and -614.29% off the current price level respectively, although investors could be excited at the prospect of a -400.0% if the CTXR share price touches on the median price of $7.00.

Let’s briefly compare Citius Pharmaceuticals Inc. (CTXR) stock to its peers. We find that current price change of 1.45% and -9.68% over the past 12 months for CTXR. Another of its peers Omeros Corporation (OMER) has dropped -1.94% previous session, and was -52.71% down over the past year. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 1.19% and 0.76%, respectively, at close of the trading.

Coming back to Citius Pharmaceuticals Inc. (NASDAQ:CTXR), we note that the average 3-month trading volume was 675.70K, while that of the preceding 10-day period stands at 1.45 million. Current shares outstanding are 146.15 million.

The insiders hold 8.40% of the company’s shares while institutions hold 11.10%. The data shows that short shares as of Oct 13, 2022, stood at 11.09 million at a short ratio of 18.47. This represents a 7.59% short interest in shares outstanding on Oct 13, 2022. Shares short rose in October from the previous month at 10.44 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 77.22% up in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *

5 Lithium Stocks with High Future Potential

Demand for lithium is expected to increase 8-fold by 2030. The world's largest automakers are racing to go green as the global EV boom continues.

 

We have collated a list of top five lithium stocks which are well positioned to benefit from the 2023 lithium boom because of their focus on multiple high-potential lithium projects.

100% free. stop anytime no spam